{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:24:14Z","timestamp":1794263054124,"version":"4.9.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clinbiochem.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T06:16:44Z","timestamp":1493878604000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma"],"prefix":"10.1016","volume":"51","author":[{"given":"Maria A.V.","family":"Willrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0005","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0010","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small b-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0015","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.mayocp.2015.06.009","article-title":"Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (msmart) consensus statement","volume":"90","author":"Dispenzieri","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0025","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (mgus) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0030","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1182\/blood-2009-08-237651","article-title":"Evidence of serum immunoglobulin abnormalities up to 9.8years before diagnosis of chronic lymphocytic leukemia: a prospective study","volume":"114","author":"Tsai","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0035","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0040","series-title":"Neoplastic Diseases of the Blood","first-page":"1431","article-title":"Waldenstrom's macroglobulinemia","author":"Kastritis","year":"2013"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0045","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1373\/clinchem.2011.171314","article-title":"Long-term biological variation of serum protein electrophoresis m-spike, urine m-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies","volume":"57","author":"Katzmann","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0055","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin d multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases","volume":"12","author":"Blade","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0060","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1515\/cclm-2015-0862","article-title":"Challenges of measuring monoclonal proteins in serum","volume":"54","author":"Keren","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0065","series-title":"Protein Electrophoresis in Clinical Diagnosis","first-page":"145","article-title":"Conditions associated with monoclonal gammopathies","author":"Keren","year":"2003"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0070","series-title":"Protein Electrophoresis in Clinical Diagnosis","first-page":"33","article-title":"Immunofixation, immunosubtraction and immunoselection techniques","author":"Keren","year":"2003"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0075","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1515\/cclm-2015-0696","article-title":"Quantification of beta-region IgA monoclonal proteins - should we include immunochemical heavylite(r) measurements? Point","volume":"54","author":"Evans","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2014.231985","article-title":"Monitoring IgA multiple myeloma: immunoglobulin heavy\/light chain assays","volume":"61","author":"Katzmann","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1373\/clinchem.2009.124461","article-title":"Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry","volume":"55","author":"Murray","year":"2009","journal-title":"Clin. Chem."},{"issue":"Pt 3","key":"10.1016\/j.clinbiochem.2017.05.001_bb0090","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/000456329102800310","article-title":"Overestimation of monoclonal immunoglobulin by immunochemical methods","volume":"28","author":"Riches","year":"1991","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International myeloma working group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0076-6879(85)16008-8","article-title":"Light chains of human immunoglobulins","volume":"116","author":"Solomon","year":"1985","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0105","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1172\/JCI107023","article-title":"The renal handling of low molecular weight proteins. Ii. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia","volume":"51","author":"Waldmann","year":"1972","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0110","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0115","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1373\/clinchem.2011.169433","article-title":"Polyclonal immunoglobulin free light chains as a potential biomarker of immune stimulation and inflammation","volume":"57","author":"Hutchison","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0120","series-title":"Neoplastic Diseases of the Blood","first-page":"1431","article-title":"Immunoglobulins and laboratory recognition of monoclonal proteins","author":"Katzmann","year":"2012"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0125","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1182\/blood-2008-02-138602","article-title":"Appraisal of immunoglobulin free light chain as a marker of response","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0130","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0135","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1373\/clinchem.2014.234757","article-title":"Heavy\/light chain assay for monitoring IgA multiple myeloma: digging out the IgA from the beta region","volume":"61","author":"Calderon","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0150","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2009.123828","article-title":"Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa\/lambda ratios","volume":"55","author":"Bradwell","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0155","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1373\/clinchem.2011.163766","article-title":"A 71-year-old woman with multiple myeloma status after stem cell transplantation","volume":"57","author":"Donato","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0160","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/leu.2012.197","article-title":"Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients","volume":"27","author":"Ludwig","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0165","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2015.253781","article-title":"Screening method for m-proteins in serum using nanobody enrichment coupled to maldi-tof mass spectrometry","author":"Kohlhagen","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0175","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of m-proteins using nanobody enrichment coupled to maldi-tof mass spectrometry","author":"Mills","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0180","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0190","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0195","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0200","first-page":"105","article-title":"Screening panels for monoclonal gammopathies: time to change","volume":"30","author":"Katzmann","year":"2009","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0205","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0210","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0215","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0220","series-title":"Cancer Facts & Figures 2016","article-title":"American cancer society","author":"Anonymous","year":"2016"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0225","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a seer-medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0235","first-page":"211","article-title":"Studies on conditions associated with disturbed gamma globulin formation (gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0240","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.0954-6820.1986.tb03349.x","article-title":"A 20-year follow-up study of 64 subjects with m-components","volume":"219","author":"Axelsson","year":"1986","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.0954-6820.1977.tb15676.x","article-title":"An eleven-year follow-up on 64 subjects with m-components","volume":"201","author":"Axelsson","year":"1977","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0250","first-page":"111","article-title":"A population study on monoclonal gammopathy. Follow-up after 5 and one-half years on 64 subjects detected by electrophoresis of 6995 sera","volume":"191","author":"Axelsson","year":"1972","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0255","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0002-9343(66)90136-7","article-title":"\u201cBenign\u201d monoclonal gammopathy: a potentially malignant condition?","volume":"40","author":"Kyle","year":"1966","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0260","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance. Natural history in 241 cases","volume":"64","author":"Kyle","year":"1978","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0265","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0270","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2003-03-0801","article-title":"Long-term follow-up of IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Kyle","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0275","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0280","article-title":"Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance in the US: estimating the burden on health care","author":"Go","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0285","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/cclm-2015-0994","article-title":"Laboratory testing in monoclonal gammopathy of renal significance (mgrs)","volume":"54","author":"Leung","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0290","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when mgus is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0295","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0300","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0310","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(14)70001-8","article-title":"Clinical course of light-chain smouldering multiple myeloma (idiopathic bence jones proteinuria): a retrospective cohort study","volume":"1","author":"Kyle","year":"2014","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0315","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1309\/AJCPT6OWWMHITA1Y","article-title":"Laboratory persistence and clinical progression of small monoclonal abnormalities","volume":"138","author":"Murray","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0320","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2016.02.034","article-title":"Prognostic impact of serum heavy\/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution","author":"Magnano","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0330","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance","volume":"22","author":"Blade","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","author":"van de Donk","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0340","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0345","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0350","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2004.05120.x","article-title":"Post-transplantation tumour load in bone marrow, as assessed by quantitative aso-pcr, is a prognostic parameter in multiple myeloma","volume":"126","author":"Bakkus","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0355","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.12576","article-title":"Clinical applicability and prognostic significance of molecular response assessed by fluorescent-pcr of immunoglobulin genes in multiple myeloma. Results from a gem\/pethema study","volume":"163","author":"Martinez-Lopez","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0360","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0365","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy","volume":"13","author":"Barnidge","year":"2014","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","author":"Mills","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0375","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1515\/cclm-2015-0699","article-title":"Screening immunofixation should replace protein electrophoresis as the initial investigation of monoclonal gammopathy: point","volume":"54","author":"Pretorius","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00277-011-1293-1","article-title":"Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain mgus in germany","volume":"91","author":"Eisele","year":"2012","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0385","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2017.05.001_bb0390","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1515\/cclm-2015-0580","article-title":"Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912016307421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912016307421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:51:15Z","timestamp":1757865075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912016307421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":78,"alternative-id":["S0009912016307421"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.05.001","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}